Elevance Health, Inc. (NYSE: ELV), once known as Anthem, Inc., stands as a behemoth in the healthcare industry with a market capitalization of $76.54 billion. The Indianapolis-based company is a formidable player in the healthcare plans sector, offering a comprehensive range of services to millions across the United States. As individual investors assess their portfolios, Elevance presents an intriguing option, especially given its potential upside of 11.84% based on current analyst price targets.
Currently trading at $346.80 per share, Elevance Health has experienced a subtle price change of 0.03%. Its 52-week range spans from $274.66 to $452.69, showcasing significant volatility and opportunity for strategic investors. The stock’s average target price set by analysts is $387.85, indicating room for growth from its present valuation.
Despite the lack of trailing P/E ratio data, Elevance Health’s forward P/E ratio of 11.71 suggests a reasonable valuation relative to expected earnings. This forward-looking metric positions Elevance competitively within the healthcare sector, where many of its peers trade at higher multiples. The company’s price is also buoyed by a solid revenue growth rate of 9.50%, reflecting its robust business model and market demand.
Elevance Health’s financial performance is further underlined by an earnings per share (EPS) figure of 25.21 and a commendable return on equity (ROE) of 13.25%. These metrics indicate effective management and a solid ability to generate profits from shareholders’ equity. Additionally, with a free cash flow of approximately $3.4 billion, Elevance is well-positioned to reinvest in growth opportunities and return value to shareholders through dividends.
Speaking of dividends, Elevance Health offers a yield of 1.98% with a payout ratio of 27.13%, signifying a healthy balance between rewarding shareholders and retaining capital for future expansion. This dividend strategy aligns with investor interests, providing a consistent income stream alongside capital appreciation potential.
Analyst sentiment towards Elevance Health is predominantly positive, with 14 buy ratings and 8 hold ratings. Notably, there are no sell ratings, underscoring confidence in the company’s strategic direction and market position. The target price range spans from $332.00 to $474.00, with the top end suggesting substantial upside potential for investors willing to withstand the inherent market fluctuations.
Technically, the stock’s 50-day moving average of $350.80 and 200-day moving average of $342.74 suggest a slight short-term dip, yet the relative strength index (RSI) of 68.13 hints at a stock nearing overbought territory. The MACD and signal line, both in negative territory, may indicate a potential for a short-term correction, offering entry opportunities for astute investors.
Elevance Health operates through four primary segments—Health Benefits, CarelonRx, Carelon Services, and Corporate & Other—offering comprehensive health plans and services. Its product suite includes employer and individual plans, Medicare and Medicaid options, and specialty services such as pharmacy and behavioral health management. This diverse portfolio not only broadens its revenue streams but also mitigates risk across various healthcare sub-sectors.
Formerly known as Anthem, the company’s rebranding to Elevance Health in June 2022 reflects its evolving focus on elevating whole health through advanced service offerings. This strategic shift is aimed at enhancing customer experience and expanding its reach in the healthcare market.
For investors considering Elevance Health, the stock offers a blend of growth potential and income generation, underpinned by strong financial fundamentals and a positive industry outlook. As the healthcare landscape continues to evolve, Elevance Health remains well-equipped to capitalize on emerging trends and deliver long-term value to its shareholders.
